Related Experiment Video
Updated: Jul 1, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
Mutasynthesis and Antibiotic Activity of Mupirocin Analogues
Sarah M Husain1,2, Luoyi Wang1,3, Li-Chen Han1
1School of Chemistry, Cantock's Close, University of Bristol, Bristol, UK.
Abstract:
With growing understanding of complex biosynthetic pathways to natural products, mutasynthesis, which combines metabolic engineering with chemical synthesis, is becoming an increasingly important tool to produce novel compounds. Mupirocin, isolated from Pseudomonas fluorescens, is a mixture of pseudomonic acids (PAs) that exhibit antibiotic activity against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus. We have developed a flexible approach, based on mutasynthesis, for the preparation of a library of novel PA analogues. The antimicrobial activities of the natural products and synthetic analogues were evaluated against Bacillus subtilis and four Staphylococcus aureus strains. Interestingly, one of the analogues retained antimicrobial activity in all the assays but lacked structural features that render PA-A unstable, that is, the 10,11-epoxide (replaced by an alkene) and ester linkage (replaced by a ketone). In addition, mutasynthesis allowed the preparation of an analogue of a key biosynthetic intermediate (desepoxy-PA-B) in which the C9 hydroxy fatty acid is replaced by a C7 analogue. Feeding studies with mutant strains of Pseudomonas fluorescens revealed that C7-desepoxy-PA-B was converted to the novel metabolite C7-PA-C with loss of the 8-hydroxyl group but with no extension to the C9 side chain.
Insights
Mutasynthesis enabled the creation of novel pseudomonic acid (PA) analogues with retained antibiotic activity. One analogue, lacking unstable features, shows promise for developing new antibacterial agents against resistant bacteria.
Area of Science:
- Natural Product Biosynthesis
- Synthetic Biology
- Medicinal Chemistry
Background:
- Mupirocin, a mixture of pseudomonic acids (PAs), possesses antibiotic properties against Gram-positive bacteria, including MRSA.
- Understanding complex biosynthetic pathways is crucial for developing novel antimicrobial compounds.
- Mutasynthesis, combining metabolic engineering and chemical synthesis, offers a powerful strategy for generating compound diversity.
Purpose of the Study:
- To develop a flexible mutasynthesis approach for creating novel pseudomonic acid analogues.
- To evaluate the antimicrobial activities of these synthetic analogues.
- To investigate the structure-activity relationships of PAs.
Main Methods:
- Utilized mutasynthesis to generate a library of novel PA analogues.
- Assessed antimicrobial activity against Bacillus subtilis and four Staphylococcus aureus strains.
- Synthesized a C7 analogue of a key biosynthetic intermediate (desepoxy-PA-B) and conducted feeding studies.
Main Results:
- One novel PA analogue retained significant antimicrobial activity while lacking the 10,11-epoxide and ester linkage found in PA-A.
- This analogue demonstrated stability by replacing the epoxide with an alkene and the ester with a ketone.
- Feeding studies confirmed the conversion of C7-desepoxy-PA-B to a novel metabolite, C7-PA-C, with modifications at the 8-hydroxyl group and side chain.
Conclusions:
- Mutasynthesis is an effective strategy for producing stable and active pseudomonic acid analogues.
- The developed analogues show potential as new antibacterial agents, particularly against resistant strains.
- Further research into these stable analogues could lead to the development of improved antibiotics.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Gram-positive Cell Wall Synthesis
Inhibitors of Bacterial Protein Synthesis
Antimicrobial Effectiveness

